Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Given “Buy” Rating at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH reissued their buy rating on shares of Armata Pharmaceuticals (NYSEAMERICAN:ARMP) in a report released on Monday morning, reports. They currently have a $9.00 price objective on the stock.

Other equities research analysts also recently issued research reports about the company. HC Wainwright set a $7.00 price objective on Armata Pharmaceuticals and gave the company a buy rating in a research report on Thursday, May 23rd. Zacks Investment Research raised GALP ENERGIA SG/ADR from a sell rating to a hold rating in a research report on Monday, May 27th.

Shares of NYSEAMERICAN:ARMP opened at $3.39 on Monday. Armata Pharmaceuticals has a 52 week low of $2.10 and a 52 week high of $19.18.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last announced its quarterly earnings data on Monday, May 6th. The company reported ($1.54) EPS for the quarter, meeting the Zacks’ consensus estimate of ($1.54).

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains.

Recommended Story: What is a front-end load?

Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with's FREE daily email newsletter.